Q-linea AB (publ) (QLINEA.ST) Research

Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.

Market snapshot

Symbol
QLINEA.ST
Price
$17.35
Day change
-5.19%
Market cap
$115.5M
P/E ratio
-0.84x
52-week range
14.55-79
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 18 days

Peer companies

  • AcuCort AB (ACUC.ST)
  • Alzinova AB (publ) (ALZ.ST)
  • BrainCool AB (publ) (BRAIN.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • Integrum AB (publ) (INTEG-B.ST)
  • iZafe Group AB (publ) (IZAFE-B.ST)
  • Klaria Pharma Holding AB (publ.) (KLAR.ST)
  • Neola Medical AB (publ) (NEOLA.ST)

Open Q-linea AB (publ) (QLINEA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.